Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
DEFA14A

Additional proxy soliciting materials - definitive

 View HTML
0001558370-19-003479.pdf
0001558370-19-003479.rtf
0001558370-19-003479.xls
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

 View HTML
0001047469-19-001772.pdf
0001047469-19-001772.rtf
0001047469-19-001772.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-19-018709.pdf
0001104659-19-018709.rtf
0001104659-19-018709.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-19-017829.pdf
0001104659-19-017829.rtf
0001104659-19-017829.xls
424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

 View HTML
0001047469-19-001686.pdf
0001047469-19-001686.rtf
0001047469-19-001686.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-004061.pdf
0001179110-19-004061.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-19-004062.pdf
0001179110-19-004062.rtf
CT ORDER

CT ORDER

 View HTML
9999999997-19-001396.pdf
9999999997-19-001396.rtf
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001179110-19-003920.pdf
0001179110-19-003920.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-19-001726.pdf
0001558370-19-001726.rtf
0001558370-19-001726.xls